dc.contributor.author
Alba Garibay, Marco Antonio
dc.contributor.author
Velasco Muñoz, César
dc.contributor.author
Simeón Aznar, Carmen Pilar
dc.contributor.author
Fonollosa Pla, Vicent
dc.contributor.author
Trapiella Martínez, Luis
dc.contributor.author
Egurbide Arberas, María Victoria
dc.contributor.author
Sáez Comet, Luis
dc.contributor.author
Castillo Palma, María Jesús
dc.contributor.author
Callejas Rubio, José Luis
dc.contributor.author
Camps García, María Teresa
dc.contributor.author
Tolosa Vilella, Carles
dc.contributor.author
Ríos Blanco, Juan José
dc.contributor.author
Freire, Mayka
dc.contributor.author
Vargas Hitos, José Antonio
dc.contributor.author
Espinosa Garriga, Gerard
dc.contributor.author
RESCLE Registry
dc.date.issued
2017-09-18T18:00:20Z
dc.date.issued
2017-09-18T18:00:20Z
dc.date.issued
2017-09-18T18:00:20Z
dc.identifier
https://hdl.handle.net/2445/115575
dc.description.abstract
Peak age at onset of systemic sclerosis (SSc) is between 20 and 50 years, although SSc is also described in both young and elderly patients. We conducted the present study to determine if age at disease onset modulates the clinical characteristics and outcome of SSc patients. The Spanish Scleroderma Study Group recruited 1037 patients with a mean follow-up of 5.2 ± 6.8 years. Based on the mean ± 1 standard deviation (SD) of age at disease onset (45 ± 15 yr) of the whole series, patients were classified into 3 groups: age ≤ 30 years (early onset), age between 31 and 59 years (standard onset), and age ≥ 60 years (late onset). We compared initial and cumulative manifestations, immunologic features, and death rates. The early-onset group included 195 patients; standard-onset group, 651; and late-onset, 191 patients. The early-onset group had a higher prevalence of esophageal involvement (72% in early-onset compared with 67% in standard-onset and 56% in late-onset; p = 0.004), and myositis (11%, 7.2%, and 2.9%, respectively; p = 0.009), but a lower prevalence of centromere antibodies (33%, 46%, and 47%, respectively; p = 0.007). In contrast, late-onset SSc was characterized by a lower prevalence of digital ulcers (54%, 41%, and 34%, respectively; p < 0.001) but higher rates of heart conduction system abnormalities (9%, 13%, and 21%, respectively; p = 0.004). Pulmonary hypertension was found in 25% of elderly patients and in 12% of the youngest patients (p = 0.010). After correction for the population effects of age and sex, standardized mortality ratio was shown to be higher in younger patients. The results of the present study confirm that age at disease onset is associated with differences in clinical presentation and outcome in SSc patients.
dc.format
application/pdf
dc.publisher
Lippincott, Williams & Wilkins. Wolters Kluwer Health
dc.relation
Versió postprint del document publicat a: https://doi.org/10.1097/MD.0000000000000018
dc.relation
Medicine, 2014, vol. 93, num. 2, p. 73-81
dc.relation
https://doi.org/10.1097/MD.0000000000000018
dc.rights
(c) Lippincott, Williams & Wilkins. Wolters Kluwer Health, 2014
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Medicina)
dc.subject
Malalties autoimmunitàries
dc.subject
Scleroderma (Disease)
dc.subject
Autoimmune diseases
dc.title
Early- versus late-onset systemic sclerosis. Differences in clinical presentation and outcome in 1037 patients
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion